Mrinalini Dey DrMiniDey
5 days 7 hours ago
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl
Md Yuzaiful Md Yusof Yuz6Yusof
5 days 11 hours ago
#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of such deep immune interventions remains uncertain.
Md Yuzaiful Md Yusof Yuz6Yusof
5 days 12 hours ago
#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow
https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi
Janet Pope Janetbirdope
5 days 12 hours ago
How many ‘cars’ are there?
crowded #CAR-T ‘driving’ innovation at
#EULAR2026
>90 abstracts w CAR-T in title
Lessons learned
Maybe #immune #reset is not always the goal
➡️vs ’#immune #dimming
How long are effects?
safety looks good
PT selection is key
Early, no damage
@RheumNow https://t.co/6jii5MBJcJ
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Janet Pope Janetbirdope
6 days 10 hours ago
#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming
➡️esp if multi drug failure already
By Hector Chinoy #WIN #IIM June5
Excellent #CAR-T review
should re think of
Total immune reset in many #SARD PTS is unlikely
EULAR2026 @RheumNow https://t.co/eqKzxzqa0z
Bella Mehta bella_mehta
6 days 11 hours ago
Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T
#POS0303 #EULAR2026 @RheumNow
24 months follow up data for 21 pts.
Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 12 hours ago
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
Nelly ZIADE 🍀 Nellziade
6 days 12 hours ago
#CAR_T cell therapy in #SSc
Promising results from the Breakfree-1 study
(Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients
More data is needed
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5
Nelly ZIADE 🍀 Nellziade
6 days 12 hours ago
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
